ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibromyalgia"

  • Abstract Number: 2849 • 2013 ACR/ARHP Annual Meeting

    Medication Adherence and Healthcare Costs Among Patients With Fibromyalgia: Combination Medication Versus Duloxetine, Pregabalin, and Milnacipran Initiators

    Nicole Marlow1, Kit Simpson2, James Zoller2 and E. Baron Short3, 1Public Health Sciences, Medical University of South Carolina, Charleston, SC, 2Healthcare Leadership and Management, Medical University of South Carolina, Charleston, SC, 3Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

    Background/Purpose: The combined use of prescription drugs (Rx) with complementary mechanisms of action has been described for treating fibromyalgia (FM). We examined medication adherence and…
  • Abstract Number: 2850 • 2013 ACR/ARHP Annual Meeting

    Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase 3 Double-Blind, Randomized Withdrawal, Placebo-Controlled Study

    Lesley M. Arnold1, Pierre Arsenault2, Cynthia Huffman3, Jeffrey L. Patrick4, Michael Messig4, Marci L. Chew4, Luis Sanin4, Lynne Pauer4 and Andrew Clair4, 1Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, 2Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, 3Meridien Research, Tampa, FL, 4Pfizer Inc, New York, NY

    Background/Purpose: Pregabalin (PGB) is currently approved for the treatment of fibromyalgia (FM) for twice daily dosing over a range of 300-450 mg/day. A pregabalin controlled-release…
  • Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting

    Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia

    John S. Sampalis1,2, Mary-Ann Fitzcharles3, Peter A. Ste-Marie4, Emmanouil Rampakakis1,2 and Yoram Shir4, 1JSS Medical Research, Montreal, QC, Canada, 2Jewish General Hospital, McGill University, Montreal, QC, Canada, 3Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 4Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
  • Abstract Number: 2092 • 2013 ACR/ARHP Annual Meeting

    Strengthening Exercises Using A Swiss Ball Improve Symptoms and Muscle Performance Of Patients With Fibromyalgia: A Randomized Controlled Study

    Josiander Arakaki Sr., RHEUMATOLOGY, UNIFESP, sao paulo, Brazil

    Background/Purpose: Fibromyalgia (FM) is a disorder characterized by chronic widespread pain, fatigue and reduced muscle strength. Exercise is fundamental to the treatment of FM and…
  • Abstract Number: 2450 • 2012 ACR/ARHP Annual Meeting

    Evoked Pain Brain Response Is Associated with Reduced μ-Opioid Receptor Binding in Fibromyalgia

    Heng Wang1, Daniel J. Clauw2, Jon-Kar Zubieta3 and Richard E. Harris4, 1Anesthesiology, University of Michigan, Ann Arbor, 2Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, 3Molecular and Behavioral Neuroscience Institue, Psychiatry, University of Michigan, Ann Arbor, 4Anesthesiology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Previous studies indicate that fibromyalgia (FM) patients have augmented clinical and brain responses to painful stimuli (i.e. hyperalgesia/allodynia), as well as increased production of…
  • Abstract Number: 1566 • 2012 ACR/ARHP Annual Meeting

    Fibromyalgia’s Impact On Relationships

    Robert S. Katz1, Alexandra Small2, Sharon M. Ferbert3 and Susan Shott1, 1Rush University Medical Center, Chicago, IL, 2University of Illinois Medical School, Chicago, IL, 3Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL

    Background/Purpose: The Fibromyalgia Syndrome (FMS) can place a strain on patients’ personal relationships. Having a close support network is helpful in coping with illnesses, but chronic…
  • Abstract Number: 806 • 2012 ACR/ARHP Annual Meeting

    Posterior Insula Combined Glutamate and Glutamine Is Associated with Pain in Fibromyalgia: A Replication Study

    Eric Ichesco1, Daniel J. Clauw2, Steven E. Harte1, Anson E. Kairys3, Johnson P. Hampson1, Tobias Schmidt-Wilcke1 and Richard E. Harris1, 1Anesthesiology, University of Michigan, Ann Arbor, MI, 2Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, 3Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI

    Background/Purpose: Central pain augmentation resulting from enhanced excitatory and/or decreased inhibitory neurotransmission is a proposed mechanism underlying the pathophysiology of functional pain syndromes such as…
  • Abstract Number: 2402 • 2012 ACR/ARHP Annual Meeting

    Clinical Utility of the Hospital Anxiety and Depression Scale for an Outpatient Fibromyalgia Education Program

    Diane Tin1, Lorna J. Bain1, J. Carter Thorne2, Seungree Nam3 and Liane Ginsburg4, 1The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3Faculty of Heatlh, York University, Toronto, ON, Canada, 4School of Health Policy and Management, York University, Toronto, ON, Canada

    Background/Purpose: The Arthritis Program (TAP) at Southlake Regional Health Centre has offered an inter-professional, patient centered Fibromyalgia (FM) education program for nearly two decades. This…
  • Abstract Number: 1487 • 2012 ACR/ARHP Annual Meeting

    Incidence of Fibromyalgia Syndrome in Systemic Sclerosis and Rheumatoid Arthritis. Comparative Results According to Clinical Diagnosis, Screening Test with Fibromyalgia Rapid Screening Tool, Diagnosis with ACR1990 and ACR 2010 Criteria

    Serge Perrot1, Mariana Peixoto2, Philippe Dieude3, Eric Hachulla4, Sébastien Ottaviani5 and Yannick Allanore6, 1Internal Medicine and Pain Clinic, Hopital Hotel Dieu, Paris, France, 2Rheumatology Department, Cochin Hospital, Paris, France, 3Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, 4Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 5Service de Rhumatologie, Hôpital Bichat, APHP, APHP, Paris, France, 6Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France

    Background/Purpose: Fibromyalgia (FMS) is a chronic widespread pain condition that may be associated with inflammatory chronic disorders like rheumatoid arthritis (RA) and systemic sclerosis (SSc).…
  • Abstract Number: 2104 • 2012 ACR/ARHP Annual Meeting

    Quantitation in Patients with Rheumatoid Arthritis of Inflammation, Joint Damage and “Unexplained Symptoms” (e.g., Fibromyalgia) in Addition to Overall Status, According to 4 Physician Global Estimates Scored 0-10

    Isabel Castrejón1, Martin J. Bergman2 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Taylor Hospital, Ridley Park, PA

    Background/Purpose: A physician global estimate (DOCGL) of patient clinical status in rheumatoid arthritis (RA) is scored by many rheumatologists entirely based on inflammation, but others…
  • Abstract Number: 954 • 2012 ACR/ARHP Annual Meeting

    Diagnosis of Secondary Fibromyalgia in an Established Rheumatoid Arthritis Cohort

    Yvonne C. Lee1, Christine K. Iannaccone1, Michelle A. Frits1, M. Weinblatt2 and Nancy A. Shadick3, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 3Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The prevalence of fibromyalgia (FM) is 7-10 times higher among rheumatoid arthritis (RA) patients than the general population.  However, the diagnosis of FM in…
  • Abstract Number: 2048 • 2012 ACR/ARHP Annual Meeting

    Four Physician Global Assessments for Overall Status, Inflammation, Damage, and Unexplained Symptoms Are Useful in Usual Care of Patients with Osteoarthritis, Fibromyalgia, Systemic Lupus Erythematosus, and Spondyloarthropathy, As Well As Rheumatoid Arthritis

    Isabel Castrejón1, Martin J. Bergman2 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Taylor Hospital, Ridley Park, PA

    Background/Purpose: A physician global estimate (DOCGL) is important in clinical decisions concerning patients with rheumatoid arthritis (RA), and often is the most efficient of the…
  • Abstract Number: 955 • 2012 ACR/ARHP Annual Meeting

    Post – Surgical Outcome Is Correlated with Pre – Surgical Symptoms of Fibromyalgia in Patients Undergoing Spinal Surgery

    Jacob N. Ablin1, Mark Berman2, Eyal Behrbalk3, Dan Buskila4, Gilad Regev3 and Zvi Lidar3, 1Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Internal Medicine F, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Department of Neurosurgery and Orthopedic, Department of Neurosurgery and Orthopedic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 4Ben-Gurion University, Beer-Sheva, Israel

    Background/Purpose: Chronic pain is a major symptom for which patients undergo spinal surgery. At the same time, chronic pain is considered an entity in and…
  • Abstract Number: 2030 • 2012 ACR/ARHP Annual Meeting

    A Multi-Modal Amplified Musculoskeletal Pain Treatment Program: Associations of Previous Pharmacotherapy with Subsequent Outcomes

    Cara M. Hoffart1, Pamela Weiss2, David D. Sherry3, Chris Feudtner4 and Margaret Stineman5, 1The Children's Hospital of Philadelphia, Philadelphia, PA, 2Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, 3Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 4Division of General Pediatrics, Children's Hospital of Philadelphia; University of Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 5The University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Management of Amplified Musculoskeletal Pain (AMP) in children (i.e. juvenile primary fibromyalgia, complex regional pain syndrome, neuropathic pain, central sensitization) remains controversial. Common practice…
  • Abstract Number: 957 • 2012 ACR/ARHP Annual Meeting

    Key Psychological Processes Associated with the Fibromyalgia Phenotype Exist On a Continuous Spectrum with Asymptomatic People

    Katrina Malin1 and Geoffrey O. Littlejohn2, 1Medicine, Monash University, Clayton, Australia, 2Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia

    Background/Purpose: The core features of the fibromyalgia phenotype, the widespread pain and widespread tenderness, represent one extreme of a continuous spectrum with asymptomatic people at…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology